Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4165780 | 0.84 | CYP1A2 (0.36) | SMN1; SMN2CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL28458714 | 0.81 | CACNA1G (0.31) | SMN1; SMN2 | |
| SCHEMBL803151 | 0.78 | POLB (0.36) | NR3C1POLBPKM | |
| SCHEMBL4682271 | 0.74 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL28757929 | 0.73 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL3158933 | 0.73 | SMN1; SMN2 (0.36) | SMN1; SMN2NR3C1POLBPKM | |
| SCHEMBL13243038 | 0.72 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL5369514 | 0.70 | LMNA (0.36) | SMN1; SMN2LMNAPOLBALDH1A1GAA | |
| SCHEMBL9671822 | 0.70 | HTT (0.33) | SMN1; SMN2CYP1A2CYP2C9GAA | |
| SCHEMBL9672831 | 0.70 | HTT (0.33) | SMN1; SMN2CYP1A2CYP2C9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680290-B2 | Isoxazoline derivatives and their use as herbicides | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| US-8680290-B2 | Isoxazoline derivatives and their use as herbicides | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| US-8680290-B2 | Isoxazoline derivatives and their use as herbicides | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| EP-1789401-B1 | ISOXAZOLINE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA LTD (GB) | 2010-03-03 | — | — | EP | disclosed |
| US-20080139390-A1 | Isoxazoline Derivatives and Their Use as Herbicides | SYNGENTA LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080139390-A1 | Isoxazoline Derivatives and Their Use as Herbicides | SYNGENTA LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080139390-A1 | Isoxazoline Derivatives and Their Use as Herbicides | SYNGENTA LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139390-A1 | Isoxazoline Derivatives and Their Use as Herbicides | MTX1, MTX2, CHRM1 | SMN1; SMN2 3441/4885CYP1A2 21/4885CYP2C9 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.